Study: NCT04826094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Env-C Plasmid DNA
Description: 2 mg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Env-C Plasmid DNA
Description: 2 mg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Env-C Plasmid DNA
Description: 2 mg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Env-C Plasmid DNA
Description: 2 mg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Env-C Plasmid DNA
Description: 2 mg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Env-C Plasmid DNA
Description: 2 mg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Env-C Plasmid DNA
Description: 2 mg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV Env gp145 C.6980 protein
Description: 100 µg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV Env gp145 C.6980 protein
Description: 100 µg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV Env gp145 C.6980 protein
Description: 100 µg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV Env gp145 C.6980 protein
Description: 100 µg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV Env gp145 C.6980 protein
Description: 100 µg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV Env gp145 C.6980 protein
Description: 100 µg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV Env gp145 C.6980 protein
Description: 100 µg per dose. Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rehydragel®
Description: Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rehydragel®
Description: Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rehydragel®
Description: Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rehydragel®
Description: Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rehydragel®
Description: Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rehydragel®
Description: Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rehydragel®
Description: Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALF43
Description: Adjuvant. Army Liposome Formulation-43% Cholesterol. 200 µg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALF43
Description: Adjuvant. Army Liposome Formulation-43% Cholesterol. 200 µg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALF43
Description: Adjuvant. Army Liposome Formulation-43% Cholesterol. 200 µg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALF43
Description: Adjuvant. Army Liposome Formulation-43% Cholesterol. 200 µg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALF43
Description: Adjuvant. Army Liposome Formulation-43% Cholesterol. 200 µg per dose. Administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: Adjuvant. Recombinant double mutant Escherichia coli heat labile toxin. 50 µg per dose. Transcutaneous application (needle-free skin patch). 1 mL diluted dmLT added to gauze pad at site of injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: Adjuvant. Recombinant double mutant Escherichia coli heat labile toxin. 50 µg per dose. Transcutaneous application (needle-free skin patch). 1 mL diluted dmLT added to gauze pad at site of injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (IM)
Description: 0.9% sodium chloride (sterile saline). Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (IM)
Description: 0.9% sodium chloride (sterile saline). Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (IM)
Description: 0.9% sodium chloride (sterile saline). Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (IM)
Description: 0.9% sodium chloride (sterile saline). Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (IM)
Description: 0.9% sodium chloride (sterile saline). Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (IM)
Description: 0.9% sodium chloride (sterile saline). Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (IM)
Description: 0.9% sodium chloride (sterile saline). Administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (TCl)
Description: Transcutaneous application (needle-free skin patch). 0.9% sodium chloride (sterile saline) added to gauze pad at site of injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (TCl)
Description: Transcutaneous application (needle-free skin patch). 0.9% sodium chloride (sterile saline) added to gauze pad at site of injection.